⚠ Supply Shortfalls Cap the OpportunityModerate threat

Lilly's incretins have been constrained by supply rather than demand — a sign of enviable popularity, but also a genuine problem, because every dose the company cannot make is revenue forgone and an opening for someone else. When a drug is in shortage, patients go untreated or seek alternatives, rivals capture the demand Lilly cannot serve, and compounding pharmacies and gray-market copies rush to fill the gap — some of which entrench themselves and prove hard to dislodge even once supply recovers.

The danger is that a prolonged inability to meet demand does lasting damage beyond the immediate lost sales. It hands Novo Nordisk and other competitors share they might not otherwise have won, it invites regulatory and political criticism over access to needed medicines, and it lets unauthorized or compounded versions build a foothold. A supply-constrained blockbuster is leaving money on the table and opportunity for rivals every day it cannot fully meet the market.

Lilly is investing aggressively to expand capacity and has been steadily relieving the constraint, and being sold out is a far better problem than weak demand. But an owner should recognize that manufacturing shortfalls have genuinely capped how much of the extraordinary incretin opportunity Lilly has been able to capture, that they have handed openings to competitors and copies, and that in a market this large and contested, the ability to actually make and deliver enough of the drug is as decisive as having the best drug in the first place — hence the ~$50B capacity build-out¹.